Systematic review of transpyloric versus gastric tube feeding for preterm infants

W McGuire, P McEwan


PREMATURE INFANTS OFTEN HAVE POOR COORDINATION OF SUCKING AND SWALLOWING, AND THIS CAN DELAY THE ESTABLISHMENT OF SAFE ORAL FEEDING. ENTERAL FEEDS MAY BE DELIVERED THROUGH A CATHETER PASSED THROUGH THE NOSE OR THE MOUTH INTO THE STOMACH OR UPPER SMALL BOWEL.

In preterm infants, the gastro-oesophageal valve is more lax, and gastric peristalsis and emptying is less effective than in term infants.\(^1\) Placement of the enteral feeding tube in the duodenum or jejunum (transpyloric) ensures delivery of enteral feeds to the main sites of nutrient absorption, and has the theoretical advantage of decreasing the potential for oesophageal reflux and aspiration of milk into the lungs. However, feeding by the transpyloric route has potential disadvantages. The gastric phase of the digestion is bypassed, and secretion of intestinal hormones and growth factors may be impaired.\(^2\) There is also a risk that potentially pathogenic organisms that would have been removed in the acidic environment of the stomach may be delivered to the small bowel.\(^3\) These factors may contribute to an increased risk of gastrointestinal disturbance or necrotising enterocolitis in infants fed by the transpyloric route, as suggested by case-control data.\(^4\) In addition, transpyloric feeding tubes are difficult to position, and, after placement, the transpyloric tube may still migrate back to the stomach. Serious adverse events, including cases of intestinal perforation and aspiration pneumonia, may have been affected by allocation bias. No significant differences were detected in the incidence of other adverse events, including necrotising enterocolitis, intestinal perforation, and aspiration pneumonia.

Conclusions: No evidence of benefit was found, but evidence of harm was found. Feeding by the transpyloric route cannot be recommended for preterm infants.

**METHODS**

We used the standard search strategy of the Cochrane Neonatal Collaborative Review Group (http://cochrane.mcmaster.ca/neonatal/). This included searches of the Cochrane Controlled Trials Register (CCTR; 2003, issue 1), Medline (1966 to April 2003), and Embase (1980 to April 2003), and references in previous reviews. The data were extracted, analysed, and synthesised using the standard methods of the Cochrane Neonatal Collaborative Review Group.

Results: Data were found from eight trials. No evidence of an effect on growth or development was found, but transpyloric feeding was associated with a greater incidence of gastrointestinal disturbance: relative risk (RR) 1.45, 95% confidence interval (CI) 1.05 to 2.09. Transpyloric feeding was also associated with increased mortality: RR 2.46, 95% CI 1.36 to 4.46. However, the trial that contributed most to this finding may have been affected by allocation bias. No significant differences were detected in the incidence of other adverse events, including necrotising enterocolitis, intestinal perforation, and aspiration pneumonia.

Conclusions: No evidence of benefit was found, but evidence of harm was found. Feeding by the transpyloric route cannot be recommended for preterm infants.

**RESULTS**

Search findings

Overall, 21 studies that appeared to be relevant were identified in the first round of screening. We then excluded 13 reports as these were unlikely to be randomised or quasi-randomised trials.\(^7\)–\(^19\)

We included eight studies, enrolling a total of 340 infants.\(^20\)–\(^27\) One of the studies\(^26\) was reported previously in...
Table 1: Specified criteria for inclusion of studies

<table>
<thead>
<tr>
<th>Studies:</th>
<th>Randomised or quasi-randomised (for example, alternate allocation, or allocation by date of birth or day of year) controlled trials.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants:</td>
<td>Preterm infants (less than 37 weeks gestation) who needed enteral tube feeding, cared for in a hospital setting.</td>
</tr>
<tr>
<td>Interventions:</td>
<td>Transpyloric versus gastric tube feeding with catheters passed through the nose or mouth. Trials of gastrostomy, duodenostomy, or jejunostomy feeding were not included.</td>
</tr>
<tr>
<td>Outcomes:</td>
<td>1. Growth, development, and feeding</td>
</tr>
<tr>
<td></td>
<td>a. Short term (before discharge from hospital) growth parameters</td>
</tr>
<tr>
<td></td>
<td>b. Longer term (after discharge from hospital) growth parameters</td>
</tr>
<tr>
<td></td>
<td>c. Neurodevelopmental outcomes during infancy and beyond using validated assessment tools</td>
</tr>
<tr>
<td></td>
<td>d. Time from birth to establish full oral feeds</td>
</tr>
<tr>
<td></td>
<td>e. Time from birth to establish full enteral tube feeds</td>
</tr>
<tr>
<td>2. Adverse events</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Death before discharge from hospital</td>
</tr>
<tr>
<td></td>
<td>b. Gastrointestinal disturbance such as diarrhoea or feeding intolerance that results in cessation of enteral feeding</td>
</tr>
<tr>
<td></td>
<td>c. Necrotising enterocolitis</td>
</tr>
<tr>
<td></td>
<td>d. Aspiration pneumonia/pneumonitis: clinical and/or radiological evidence of lower respiratory tract compromise attributed to covert or evident aspiration of gastric contents</td>
</tr>
<tr>
<td></td>
<td>e. Intestinal perforation</td>
</tr>
<tr>
<td></td>
<td>f. Pyloric stenosis requiring surgical intervention</td>
</tr>
<tr>
<td></td>
<td>g. Chronic lung disease: additional oxygen requirement at 36 weeks post-conception</td>
</tr>
</tbody>
</table>

Table 2: Characteristics of included studies: participants, intervention, and outcome

<table>
<thead>
<tr>
<th>Trial (year)</th>
<th>Participants</th>
<th>Interventions (feeding route)</th>
<th>Duration</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew (1979)</td>
<td>Appropriate for gestational age infants, birth weight &lt;1500 g, not needing assisted ventilation</td>
<td>Nasojejunal: n = 32, Nasogastric: n = 24</td>
<td>Until achieving an enteral intake of 200 ml/kg/day</td>
<td>Growth, Adverse events</td>
</tr>
<tr>
<td>Loi (1986)</td>
<td>Appropriate for gestational age infants, birth weight &lt;1500 g, Formula fed infants, birth weight &lt;1400 g</td>
<td>Continuous nasoduodenal: n = 45, Intermittent nasogastric: n = 35, Continuous nasogastric: n = 15, Balus nasogastric: n = 15</td>
<td>Seven weeks</td>
<td>Growth, Adverse events</td>
</tr>
<tr>
<td>Macdonald (1992)</td>
<td>Infants, birth weight &lt;1700 g or gestation &lt;33 weeks</td>
<td>Continuous nasogastric: n = 13, Continuous nasojejunal: n = 26</td>
<td>Until weight &gt;1600 g</td>
<td>Growth, Adverse events</td>
</tr>
<tr>
<td>Pereira (1981)</td>
<td>Infants, birth weight &lt;1700 g or gestation &lt;33 weeks</td>
<td>Continuous nasojejunal: n = 27</td>
<td>Until breast feeding</td>
<td>Growth, Adverse events</td>
</tr>
<tr>
<td>Roy (1975)</td>
<td>Appropriate for gestational age infants, birth weight &lt;1500 g, not needing assisted ventilation</td>
<td>Continuous nasojejunal: n = 12, Intermittent nasogastric: n = 9</td>
<td>Seven days</td>
<td>Growth</td>
</tr>
<tr>
<td>Van Caillie (1975)</td>
<td>Preterm infants, birth weight &lt;1300 g</td>
<td>Continuous nasoduodenal: n = 6</td>
<td>40 days</td>
<td>Growth, Adverse events</td>
</tr>
<tr>
<td>Wells (1975)</td>
<td>Preterm infants, birth weight &lt;1500 g</td>
<td>Continuous nasogastric: n = 5, nasojejunal: n = 1</td>
<td>21 days</td>
<td>Growth, Adverse events</td>
</tr>
<tr>
<td>Whitfield (1982)</td>
<td>Appropriate for gestational age infants, birth weight 1000–1500 g</td>
<td>Continuous nasoduodenal: n = 28, Continuous nasogastric: n = 16</td>
<td>Until weight &gt;1500 g</td>
<td>Growth (until six months old), Adverse events</td>
</tr>
</tbody>
</table>

Growth, development, and feeding

Five studies reported changes in weight, length, and head circumference. There were no significant differences in the growth variables in any of the trials. We undertook meta-analyses where sufficient data (mean and standard deviation) were available, and these did not show any significant differences. One study reported longer term (after hospital discharge) growth. At the expected date of delivery, weight and head circumference were significantly less in the transpyloric than the gastric group. There were no significant differences at three months and six months after the expected date of delivery. However, because of loss to follow up, mainly in the transpyloric feeding group, these data should be interpreted cautiously.

The two studies that reported the time taken to establish full enteral tube feeding did not find any significant differences. The time taken to establish full oral feeding was not reported by any of the included studies.

Adverse events

Adverse events were often reported as withdrawal criteria, rather than as defined outcome measures. In most of the reports, we determined the incidence of adverse events for the complete or near complete cohort.

Death before discharge from hospital

Six trials reported this outcome. One trial found that transpyloric feeding was associated with a significantly higher mortality, but this finding may have been affected...
Transpyloric feeding for preterm infants

Table 3  Methodological quality of included studies

<table>
<thead>
<tr>
<th>Trial</th>
<th>Method of randomisation</th>
<th>Allocation concealment</th>
<th>Blinding of intervention</th>
<th>Complete follow up</th>
<th>Blinding of assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew</td>
<td>Alternate</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Loing</td>
<td>Alternate</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Macdonald</td>
<td>Sealed envelope</td>
<td>Yes</td>
<td>Can’t tell</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Pereira</td>
<td>Can’t tell</td>
<td>Can’t tell</td>
<td>Can’t tell</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Ray</td>
<td>Alternate</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Van Caille</td>
<td>Alternate</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Wells</td>
<td>Alternate</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Whitfield</td>
<td>Alternate months</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

by allocation bias. In a meta-analysis, there was a significantly higher rate of death in the infants who were fed by the transpyloric route: RR: 2.5 (95% CI 1.4 to 4.5); RD: 0.16 (95% CI 0.07 to 0.26). When the study with possible allocation bias was excluded, the increase in mortality in the transpyloric group was not quite significant: RR: 2.2 (95% CI 0.9 to 5.4); RD: 0.1 (95% CI 0.00 to 0.2).

Gastrointestinal disturbance
None of the seven trials that reported this outcome found any significant difference. Meta-analysis showed a significantly increased risk of gastrointestinal disturbance in the infants fed by the transpyloric route: RR: 1.5 (95% CI 1.1 to 2.1); RD: 0.1 (95% CI 0.02 to 0.17). A significant difference remained when the study with possible allocation bias was removed: RR: 1.4 (95% CI 1.02 to 2.0); RD: 0.1 (95% CI 0.01 to 0.21).

Necrotising enterocolitis
None of the seven trials that reported this outcome, nor a meta-analysis of the studies, found any significant difference: RR: 0.6 (95% CI 0.3 to 1.5); RD: −0.03 (95% CI −0.09 to 0.03).

Aspiration pneumonia
None of the four trials that reported this outcome, nor a meta-analysis, found any significant difference: RR: 1.4 (95% CI 0.4 to 4.2); RD: 0.02 (95% CI −0.06 to 0.1).

Intestinal perforation
None of the four trials that reported this outcome, nor a meta-analysis, found any significant difference: RR: 2.3 (95% CI 0.1 to 50.1); RD: 0.01 (95% CI −0.05 to 0.08).

Pyloric stenosis and chronic lung disease
These outcomes were not reported in any of the trials.

DISCUSSION
We have found evidence that transpyloric feeding is associated with increased mortality in preterm infants. However, many of the studies included in the review had a variety of methodological weaknesses, and this finding should be interpreted with caution. In particular, the outcomes for the largest included trial may have been affected by preferential allocation of some of the less mature or sicker infants to transpyloric feeding. When this study was excluded from the meta-analysis, the increase in mortality was not quite significant.

We also found the incidence of gastrointestinal disturbance to be significantly higher in infants fed by the transpyloric route. “Gastrointestinal disturbance” included a variety of clinically important problems such as abdominal distension, gastric bleeding, and bilious vomiting, which resulted in cessation of enteral feeding. Most of the trials recruited infants of birth weight less than 1500 g, but infants with intrauterine growth restriction were excluded in at least six of the trials. As this subpopulation may be at increased risk of adverse events related to enteral feeding, this factor limits the applicability of the findings of this review. In addition, although it may have been pragmatic to compare continuous transpyloric feeding with intermittent or bolus gastric feeding, as was the case in seven of the included studies, it should be noted that this covariate may also have affected the outcomes. The Cochrane review that compared continuous nasogastric tube feeding with intermittent bolus feeding for very low birthweight infants concluded that the clinical benefits and risks could not be reliably discerned from the available data.

We did not find any evidence that feeding by the transpyloric route compared with the gastric route affects the rate of growth. However, in many of the trials, the growth data from infants who developed complications during the study period, or in whom enteral tube placement was unsuccessful, were not reported. In the largest included trial, only 41 of the 80 infants who entered the study were included in the growth data analysis. In another trial, there were outcome data for only 44 of the 66 infants allocated to a feeding route. It may be that repeated failed attempts to position the transpyloric tube introduced a delay in starting or establishing nutritional input. As it is plausible that such a delay may affect growth, the findings may have been different in a true intention to treat analysis.

A clinically plausible putative benefit of transpyloric tube feeding is a reduced risk of aspiration pneumonia. This review did not find any evidence that this is the case. The narrow 95% confidence intervals, estimating the effect to lie between a 5% reduction in risk and a 10% increase in risk, suggest that a modest effect on aspiration pneumonia has not been missed.

Conclusion
The limited available evidence suggests that the transpyloric route should not be used routinely for preterm infants who require enteral tube feeding. The lack of evidence of any benefit, and the finding of an increased risk of gastrointestinal disturbance and possibly of death, suggest that a randomised controlled trial of transpyloric versus gastric tube feeding in preterm infants is not a priority.

Authors’ affiliations
W McGuire, P McEwan, Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK

REFERENCES
Systematic review of transpyloric versus gastric tube feeding for preterm infants

W McGuire and P McEwan

Arch Dis Child Fetal Neonatal Ed 2004 89: F245-F248
doi: 10.1136/adc.2002.022459

Updated information and services can be found at:
http://fn.bmj.com/content/89/3/F245

These include:

References

This article cites 29 articles, 9 of which you can access for free at:
http://fn.bmj.com/content/89/3/F245#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Child health (1515)
- Infant health (857)
- Neonatal health (928)
- Clinical trials (epidemiology) (252)
- Epidemiologic studies (929)
- Pneumonia (infectious disease) (40)
- TB and other respiratory infections (70)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/